This activity has expired. CME/CE credit is no longer available and the following content may not be up-to-date.
Start the program by clicking on the Start Program icon at the bottom of this page.
Program Title
Molecular Markers in GBM
Release Date: May-20-09
Credit Expiration Date: May-31-10
Program Developer/Facilitator
Medical Communications Media, Inc.
Target Audience
This educational activity is designed to meet the needs of neurosurgeons, neuro-oncologists, radiation oncologists, medical oncologists, and other healthcare providers interested in the treatment of primary gliomas.
Credit Hours
CME 0.25
Medium
e-Monograph/Video
Program Description
THIS PROGRAM INCLUDES A SHORT VIDEO CONTAINING INFORMATION THAT IS AN INTEGRAL PART OF THIS EDUCATIONAL ACTIVITY. TO APPLY FOR CME CREDIT, IT WILL BE NECESSARY TO WATCH THIS VIDEO.
The search for effective treatments for malignant gliomas first necessitates a thorough understanding of their genetic composition. Unraveling the biologic mysteries of these tumors has yielded information about some molecular biomarkers that can potentially be used to better predict patient prognosis and aid in treatment selection. This brief educational activity highlights information about some of these promising indicators.
Learning Objectives
Upon completion of this educational activity, the participant should be able to:
1.
Describe emerging concepts and treatments in the management of brain tumors.
2.
Name one molecular marker that is thought to be a prognostic indicator.
Faculty
Arnab Chakravarti, MD
Chair & Professor, Department of Radiation Oncology
Ohio State University Medical School
Co-Director, Brain Tumor Program
Arthur G. James Comprehensive Cancer Center and
Richard L. Solove Research Institute
Columbus, OH
Susan Pannullo, MD
Director of Neuro-Oncology
Weill Medical College of Cornell University
New York, NY
Michael A. Vogelbaum, MD, PhD
Associate Director, Brain Tumor and Neuro-Oncology Center
Director, Center for Translational Therapeutics
Cleveland Clinic
Cleveland, OH
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Dr. Chakravarti
discloses that he serves on the speakers’ bureau of Schering-Plough and is a consultant for Genentech.
Dr. Pannullo
discloses that she has received research funds from Cytec, Genentech, MGI Pharma, Novocare, and NTI Pharmaceuticals. She is also on speakers' bureaus for MGI Pharma and Schering-Plough.
Dr. Vogelbaum
discloses that he serves on advisory committees for MGI Pharma, Neopharm, and Schering-Plough. He is also on the speakers’ bureau for Schering-Plough.
Commercial Support Statements
This activity is supported by an educational grant from Schering-Plough.
Instructions
1.
Please turn off all pop-up blockers and click on the "Start Program" icon at the bottom of the page. If you have not previously registered with this website, you will be taken to the login/registration page where you will be able to register as a new GliomaEd.com member. If you have previously registered, you will be asked to verify or correct existing registration information. When ready, click on the "Start Program" icon.
2.
Read the text and watch the accompanying video.
3.
This program, post-test, and evaluation will take approximately 15 minutes to complete.
4.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 100% on the post-test is required for a CME certificate. One retake is permitted.
Certificate Fee
$0.00
Disclaimer
© 2009. All rights reserved. None of the contents of this publication may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the faculty members and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Schering-Plough. Any medications, diagnostic procedures, or treatments discussed by the faculty members should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.
Related Programs
Title
Audience
Medium
